A carregar...
Satralizumab: First Approval
Satralizumab (Enspryng(®)), a humanized anti-interleukin-6 (IL-6) receptor monoclonal recycling antibody, has been developed by Chugai Pharmaceutical and Roche for the treatment of neuromyelitis optica spectrum disorder (NMOSD). In June 2020, based on positive results from two pivotal phase III tria...
Na minha lista:
| Publicado no: | Drugs |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7522096/ https://ncbi.nlm.nih.gov/pubmed/32797372 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01380-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|